[ad_1]
Arecor Therapeutics (LON:AREC – Get Free Report) released its earnings results on Thursday. The company reported GBX (7) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a negative net margin of 176.89% and a negative return on equity of 118.67%.
Arecor Therapeutics Trading Up 19.7%
AREC traded up GBX 14.30 during trading on Thursday, hitting GBX 86.80. 132,247 shares of the company’s stock were exchanged, compared to its average volume of 35,933. The company has a current ratio of 1.37, a quick ratio of 6.24 and a debt-to-equity ratio of 5.51. Arecor Therapeutics has a 1 year low of GBX 35.40 and a 1 year high of GBX 100. The stock has a 50 day moving average price of GBX 63.89 and a 200 day moving average price of GBX 50.04. The firm has a market cap of £32.77 million, a P/E ratio of -280.00 and a beta of -0.18.
Arecor Therapeutics Company Profile
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products.
Further Reading
Receive News & Ratings for Arecor Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arecor Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
ABMN Staff
Source link